Glimepiride / Rosiglitazone Dosage
This dosage information may not include all the information needed to use Glimepiride / Rosiglitazone safely and effectively. See additional information for Glimepiride / Rosiglitazone.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Diabetes Type 2
The initial dosages of glimepiride-rosiglitazone are based on the current doses of sulfonylurea monotherapy and/or rosiglitazone.
For patients inadequately controlled on sulfonylurea monotherapy or who have initially responded to rosiglitazone alone and require additional glycemic control, the usual starting dose of glimepiride-rosiglitazone is 1 mg-4 mg or 2 mg-4 mg once daily. When switching from combination therapy of rosiglitazone plus glimepiride as separate tablets, the usual starting dose of glimepiride-rosiglitazone is the dose of rosiglitazone and glimepiride already being taken. The maximum recommended daily dose of glimepiride-rosiglitazone is 4 mg of glimepiride and 8 mg of rosiglitazone.
Glimepiride-rosiglitazone should be taken with the first meal of the day.
Renal Dose Adjustments
Patients with renal insufficiency should be started on glimepiride-rosiglitazone 1 mg-4 mg and carefully titrated.
Liver Dose Adjustments
Patients with mildly elevated serum transaminase levels at baseline (ALT 1 to 2.5 times the upper limit of normal) or during therapy, should be evaluated to determine the cause of the liver enzyme elevation. Initiation or continuation of therapy should proceed with caution and include close clinical monitoring in addition to frequent evaluation of liver enzymes.
Rosiglitazone therapy should not be initiated in patients with increased serum transaminase levels (ALT greater than 2.5 times the upper limit of normal).
If at any time liver enzymes increase to greater than 3 times the upper limit of normal, liver enzymes should be rechecked as soon as possible. If ALT levels remain greater than 3 times the upper limit of normal, rosiglitazone should be discontinued.
Patients with hepatic insufficiency should be started on glimepiride-rosiglitazone 1 mg-4 mg and carefully titrated.
Patients who may be more sensitive to glimepiride, including the elderly, debilitated, or malnourished, and those with adrenal insufficiency, should be started on glimepiride-rosiglitazone 1 mg-4 mg and carefully titrated.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Data not available
US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for glimepiride-rosiglitazone. It includes a Medication Guide, elements to assure safe use, and implementation system. Additional information is available at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm.